When I started writing my recent article on COVID-19 testing, I assumed that I would be doing a compare and contrast sort of article. Like many people, I assumed that the “gold standard” test would be the reverse transcriptase-polymerase chain reaction (RT-PCR) test that I described in some detail. And indeed it is, but it’s not without its problems, such as the lack of certified labs and the need for trained technicians to run the samples. I also assumed there would be another test, a simple serological test that could use antibodies to discern if there was an active or even a previous, resolved infection.
At the time I wrote the first article, I could find no indication of an immunologic test for COVID-19 (more specifically, a test for SARS-Cov-2, the virus that causes COVID-19). But almost as rapidly as the number of COVID-19 cases rises, the news changes, and it appears that simple, rapidly performed antibody tests are now or soon will be available. They likely won’t replace the gold standard RT-PCR test, but they do stand to be a game-changer for the front line providers and the victims of this disease. So it pays to take a quick look at immunoassays for infectious diseases, and learn how they work.
Continue reading “Coronavirus Testing Follow-Up: Rapid Immunologic Testing”
Alternately referred to as the “DARPA Experimental Spaceplane”, the vehicle was envisioned as being roughly the size of a business jet and capable of carrying a payload of up to 2,300 kilograms (5,000 pounds). It would take off vertically under rocket power and then glide back to Earth at the end of the mission to make a conventional runway landing. At $5 million per flight, its operating costs would be comparable with even the most aggressively priced commercial launch providers; but with the added bonus of not having to involve a third party in military and reconnaissance missions which would almost certainly be classified in nature.
